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Abstract
Background: 30 patients, with T1 renal cell carcinomas (RCC) who underwent open enucleoresection of the tumour, 
were randomized to the use of a topical haemostatic agent (Floseal) or to an infrared-sapphire coagulator (ISC), to 
compare their efficacy in achieving haemostasis. Methods: Successful intra-operative haemostasis, intra- and post-
operative bleeding, operative time, hospital discharge were evaluated.
Results: Statistically higher rates of successful haemostasis and shorter time-to-haemostasis (8,1 vs 12,9 min) were 
observed in the FloSeal group (p < 0.001 both). Patients operative time was not different between Group 1 vs 2 (58.7 ± 
12 vs 62.4 ± 15; p > 0.05). The average blood loss during surgery was less (60 +/- 25.5 mL) for the FloSeal group than for 
the ISC group (85 +/- 40.5 mL) (p < 0.05). Postoperative blood loss was 25 +/- 5 mL and 40 +/- 45 mL for Floseal and ISC 
respectively, (p < 0.05). Length of the postoperative hospital discharge was 2.5 +/- 1.2 days for FloSeal group and 3.5 +/
- 1.3 for the Group 2 (p < 0.05). No major immediate or delayed complications were observed in either Groups.
Conclusions: The use of Floseal and ISC offer a safe and efficacy haemostasis in the enucleoresection of RCC. Moreover, 
our results show a less intra-operative and post-operative blood loss as well as a shorter time to haemostasis of Floseal 
in respect to ISC.
Background
As the number of minimally invasive and laparoscopic
procedures increases, haemostatic agents (HAs) are
becoming more popular as a means of achieving rapid
haemostasis. Although the recently widespread accep-
tance, confusion still persists about their indications for
use and the optimal agent choice. They comprise a wide
range of components including topical hemostats, anti-
fibrinolytics, fibrin sealants and matrix hemostats. Topi-
cal HAs composed of a gelatin-based matrix and throm-
bin have been reported to be effective, in addition to
traditional means, in terminating bleeding during cardiac
operations in comparison with haemostatic patches or
sponges composed of either oxidized regenerated cellu-
lose or purified porcine skin gelatin [1]. The haemostatic
efficacy and handling of gelatin-thrombin matrix has
been proven also in the uterine bleeding, during abdomi-
nal myomectomy and, in thyroid surgery [2-5]. Adequate
haemostasis is extremely important in neurosurgery. In
patients with supratentorial intracerebral hematomas
FloSeal, injected into the surgical cavity, has reduced
brain exposure, damage to the surrounding tissue and the
length of surgery. Furthermore, application of FloSeal at a
laminectomy site may be useful to decrease adhesion at
the interface between the dura mater and the epidural
fibrosis [6,7]. Moreover, the management of intradural
bleeding during extended endoscopic endonasal surgery
has been challenged by applying a thrombin-gelatin hae-
mostatic matrix, useful for both oozing and focal hemor-
rhage and effective even for high-flow bleeding [8].
Recently, Izzo et al. reported a large prospective study
with the use of HAs in patients undergoing major hepatic
surgery providing a rapid and effective intra-operative
control of mild to severe bleeding from the liver edge [9].
In animal models, comparing safety, efficacy, presence of
residual material and foreign body reaction of commonly
used agents such as microporous polysaccharide hemo-
spheres (Arista), oxidized cellulose (Surgicel), microfibril-
lar collagen (Avitene) and gelatin matrix thrombin
sealant (FloSeal) emerged that Arista, Avitene, FloSeal,
and Surgicel performed better haemostasis; residual
material was not present with Arista, contrasting with its
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presence in 100% of lesions using Avitene, FloSeal, and
Surgicel; furthermore Avitene and FloSeal demonstrated
a propensity for causing granuloma formation, whereas
Arista and Surgicel showed no such evidence. Arista
degrades more rapidly than Surgicel, Avitene and FloSeal
and it does not result in any foreign body reaction [10].
Focusing on the urologic applications of tissue glues
and HAs, they have been used in the management of gen-
itourinary injuries, surgical wounds, and complications.
The best evidence for efficacy and safety exists for hae-
mostasis, especially for nephrectomy and trauma. Newer
data highlight urinary tract reconstruction, fistula and
percutaneous tract closure, suture line strengthening and
infertility as potential uses.
Partial nephrectomy (PN) is a procedure frequently
reserved for small, peripherally located renal tumours
and the intra- and post-operative haemorrhage repre-
sents the most significant risk associated to surgery.
Based upon such considerations and as HAs have
become increasingly employed across all surgical fields,
we aim to compare the safety and efficacy of a haemo-
static matrix sealant agent, FloSeal with an infrared-sap-
phire coagulator (ISC), during open enucleoresection of
renal cell carcinoma (RCC), to minimize or avoid sutur-
ing and warm ischemia time.
Methods
From January 2006 and June 2009 all patients affected by
a  R C C  w e r e  c o n s i d e r e d  f o r  t h i s  s t u d y .  O f  t h e s e ,  w e
enrolled only who has been selected to undergo a lumbar
renal enucleoresection. Criteria required for performing
an enucleoresection were a peripheral RCC with a diame-
ter less or equal to 4 cm (stage T1a) [11]. Enucleoresec-
tion means to remove the tumor and its pseudocapsule
with a normal renal parenchyma margin. With a blunt
dissection by using monopolar electrocautery, the cap-
sule of the tumour was incised circular about 5 mm
around and the mass removed. The same surgeon per-
formed all operations by a lumbar access.
Of 38 eligible patients, 8 declined to participate in the
study and a total of 30 subjects were enrolled. The
research has been carried out in accordance with the
Declaration of Helsinki and approved by the Ethics Com-
mittee of our hospital. Consent was obtained from all
patients after full explanation of the procedure. Patients
were randomly assigned to one of the two haemostatic
approaches: 15 (Group 1) to FloSeal (5,000 U/5 mL) (Bax-
ter Inc, Deerfield, IL) and 15 (Group 2) to ISC (Saphir-
Koagulator ISK 250, NK-OPTIK, München). Randomiza-
tion number was assigned by using a random allocation
software.
Before surgical treatment, subjects were evaluated with
a detailed history, physical examination, standard blood
chemical analyses, upper urinary tract and bladder ultra-
sound, abdomen computerized tomography without and
with intravenous contrast medium.
FloSeal is composed of a bovine-derived gelatin matrix
component and of a human-derived thrombin compo-
nent; it works on wet, actively bleeding tissue. After iden-
tifying the source of bleeding at the tissue surface,
manually a gauze sponge is approximated against the
bleeding surface and with the applicator tip Floseal is
applied between the sponge and the bleeding surface to
create a small hill at the source of bleeding. The gauze
sponge holds Floseal in place, against the bleeding sur-
face. To minimize disruption of the clot, the gauze
sponges is removed after hemostasis has been achieved.
ISC works through the conversion of light into thermal
energy upon absorption by the bleeding tissue causes
coagulation and haemostasis. By the ISC, light (wave
length: 0.4-3 μm, power: 120W) from a halogen lamp is
being transmitted to the bleeding tissue via a sapphire
crystal, which is non-adhesive and of high thermal resis-
tance. ISC is focused against the bleeding surface as long
is necessary to achieve haemostasis.
The study endpoints for the evaluation of haemostatic
efficacy were the rate of successful intra-operative hae-
mostasis (identified by cessation of bleeding) and time
required for haemostasis, overall post-operative bleeding,
rate of transfusion, rate of surgical revision for bleeding
and post-operative morbidity, were evaluated. The out-
come measures were the patient's operative time, blood
loss, intra-operative and post-operative complications,
and length of hospitalization.
SPSS for Windows (version 10.0.7) computer package
was used for statistical analysis. In order to detect a dif-
ference of 30% between the 2 groups in the effect size
(two-side type I error of 5% and type II error of 0.2%) 30
patients were necessary. Statistical significance was
accepted if p < 0.05. All statistical tests were two-tailed.
As variables were not normally distributed (Shapiro-Wilk
test; P < 0.05) continuous variables were analyzed with
Wilcoxon-Mann Whitney Rank Sum Test. Categorical
v a r i a b l e s  b e t w e e n  g r o u p s  w e r e  c o m p a r e d  w i t h  C h i -
square test or with Fisher's exact test when requested.
Results
17 men and 13 women with a median age of 52.5 years
(Group 1 vs 2; p > 0.05), were enrolled. In Table 1 we
report the demographic characteristics and preoperative
parameters of patients enrolled. As showed in the com-
puterized tomography, the depth of penetration of
tumors ranged from 1 to 3 cm (median 1,9 cm), without a
direct contact with the upper excretory urinary tract
(renal pelvis) in each of the patients enrolled. The tumor
diameter ranged from 2.0 to 4.0 cm (median 3.3 cm), in
both groups (p > 0.05). Renal hilar clamping was not
required. Excision was performed with a monopolar elec-Pace et al. World Journal of Surgical Oncology 2010, 8:37
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trocautery, and final haemostasis was obtained with
FloSeal (Group 1) or with ISC (Group 2), without sutur-
ing. Statistically higher rates of successful haemostasis
and shorter time-to-haemostasis (8,1 vs 12,9 min) were
observed in the FloSeal group (p < 0.001 both) (Table 2).
Patients operative time was not different between Group
1 vs 2 (58.7 vs 62.4; p > 0.05). The average blood loss dur-
ing surgery was less for the FloSeal group than for the ISC
group (60 vs 85 mL; p < 0.05). Postoperative median
blood loss through the Jackson-Pratt drain was 25 mL for
the FloSeal group and 46 mL for the control group (p <
0.05). In addition, wound drain removal occurred earlier,
the day after surgery, with FloSeal (p = 0.04 vs. group 2).
Transfusion of blood products and revision for bleeding
were not required. Median length of the postoperative
hospital discharge was 2.5 days for FloSeal group and 3.5
for the Group 2 (p < 0.05). Patients' discharge and
removal of drains has been decided by the clinicians
blinded to the treatment allocation.
No major immediate or delayed complications were
observed in either Groups. Pathology revealed a 90% of
clear cell RCC, 8% of papillary and 2% of chromophobe
RCC (Group 1 vs 2; p > 0.05). All margins of resection
were negative. At a mean follow-up of 15 months (6-37
months) no recurrence was observed. Among all patients,
the mean preoperative serum creatinine was 0.9 mg/dL,
and the average level at a mean of 12 months postopera-
tively was 1.0 mg/dL (Group 1 vs 2; p > 0.05).
Discussion
Topical HAs are classified by the FDA as absorbable or
non-absorbable, or as sealants (liquid adhesives) and
dressing (solid matrix) [12]. As it should be hard to con-
duct clinical trials on the use of HAs in several different
surgical fields due to the individual variability of patients,
there are not defined indications as regard their efficacy
and safety and about how to choose the appropriate hae-
mostatic. Several studies have been carried on to investi-
gate the haemostatic capacity and stability of different
HAs like gelatin (sponge and matrix), bovine thrombin,
freeze-dried recombinant factor VIIa and microporous
polysaccharide hemispheres, in experimental traumatic
bleeding models) [13]. The reduction in blood loss after
liver injury and in a grade 5 renal injury, with no delayed
Table 2: Intra-operative and post-operative results
Group 1 Group 2 P values
Operative time (min) 58.7 (46.7-70.7) 62.4 (47.4-77.4) >0.05 2
Time to haemostaisis (min) 8,1 (7-9.1) 12,9 (10.7-15) <0.001 2
Intraoperative blood loss (mL) 60 (34.5-85.3) 85 (44.3-125.2) <0.05 2
Postoperative blood loss (mL) 25 (23.3-50.1) 46 (35.3-90.2) <0.05 2
Drain removal (days) 1 (1-2) 3 (1-4) 0.04 2
Hospital discharge (days) 3 (2-4) 4 (4-6) <0.05 2
1χ2 corrected test or Fisher's Exact test; 2 Wilcoxon-Mann Whitney Rank Sum Test.
Table 1: Demographic and pre-operative parameters of patients enrolled
Group 1 (15 patients) Group 2 (15 patients) P values
Age (years) 51 (39-62) 53 (40-65) 0.26 2
Gender n (%) Male 8 (53%)
Female 7 (47%)
Male 9 (60%)
Female 6 (40%)
0.08 1
0.09 1
Depth of penetration of tumors in renal parenchyma 1.9 (0.8-3.0) 1.9 (1.0-2.9) 0.90 2
Tumor diameter 3.3 (2.4-4.1) 3.3 (2.1-4.5) 0.94 2
1χ2 corrected test or Fisher's Exact test; 2 Wilcoxon-Mann Whitney Rank Sum Test.Pace et al. World Journal of Surgical Oncology 2010, 8:37
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bleeding and nephrotoxicity, suggests a possible employ
for FloSeal in the treatment of devastating renal injuries
[14,15]. Furthermore, a porcine model investigating on
the use of FloSeal and Tisseel in vascular and collecting-
system injury during partial nephrectomy has showed
that Tisseel alone is not adequate for either haemostasis
or management of major collecting-system injury, while
Floseal appears sufficient to control major vascular and
collecting-system injuries [16]. All those studies paved
the way for a large use of the aforementioned sealants in
several surgical fields. In the urologic surgery, Floseal has
been used for tubeless percutaneous nephrolithotomy in
patients rendered completely stone free, administrating
the haemostatic gelatin matrix to the nephrostomy tract,
achieving immediate haemostasis and avoiding the place-
ment of a nephrostomy tube [17,18]. With increasing sur-
gical skills and novel methods of haemostasis,
laparoscopic PN (LPN) has become an attractive treat-
ment option for selected renal tumors [19,20]. In per-
forming LPN, FloSeal and BioGlue have been proposed to
avoid surgical bolsters or parenchymal sutures and to
make more surgeons comfortable with the intricacies of
laparoscopic suturing [21,22]. A recent survey on the cur-
rent practice for urologists performing LPN, confirmed
that HAs and/or glues were used in 77.4% of cases and
were mainly represented by gelatin matrix thrombin
(FloSeal), fibrin gel (Tisseel), bovine serum albumin (Bio-
Glue), cyanoacrylate glue (Glubran), oxidized regener-
ated cellulose (Surgicel), or combinations of these. The
overall postoperative bleeding requiring transfusion and
urine leakage rates were 2.7% and 1.9%, respectively [23-
29].
The widespread use of modern radiological techniques
substantially changed clinical presentation of RCC in the
last decades and, more than one half of all patients with
surgically localized renal tumors are detected inciden-
tally. All this lead to an increased interest in nephron-
sparing surgery (NSS) for the treatment of small tumors.
Enucleoresection is one of the NSS techniques available
for the elective treatment of small RCC in stage T1a,
allowing long-term cancer specific survival rates without
an increased risk of local recurrence. We have chosen to
perform the enucleoresection in a selected group of
patients comparing two ways of achieving haemeostasis
by FloSeal and ISC, in the attempt to verify differences
related to time to haemostasis, blood loss, operative time
and to spare or avoid renal parenchymal damage by heat
and suturing. Our results were in accord with those
reported in the current literature [30]. By applying Floseal
during open enucleoresection of RCC, bleeding was effi-
ciently controlled in all patients treated and none
required post-operative transfusions or showed signifi-
cant post-operative blood loss. Mostly important we
compared the haemostatic efficiency of Floseal with the
unusual application in the kidney surgery of ISC. ISC has
been developed for the haemostasis of parenchymatous
haemorrhage, mainly liver and spleen, showing that the
time until haemostasis takes place was reduced 60% and
depth of necrosis 25% in comparison to usual diathermia.
Also by using the ISC, we achieved good results in term
of bleeding control even if with longer time to haemosta-
sis respect to FloSeal and a greater intra-operative blood
loss. HAs like Floseal, used in the enucleresection of
RCC, offer a good haemostatic control without the need
of suturing. This suggestion is supported by our experi-
ence as we reached a satisfying haemostasis by applying
the HA all over the wound ground or by using the infra-
red light on the bleeding sites.
Based on more recent data, FloSeal has been experi-
mented in the robotic laparoscopic radical prostatectomy
(RP) in the attempt to develop techniques cautery-free,
clip-free and nerve-sparing that preserve the neurovascu-
lar bundles and minimize trauma, even if the effect on
potency still needs further follow-up [31,32].
As the indications for topical HAs increase in urology,
the question arises about what happens to these agents
when they enter the urinary collecting system. It has been
shown that fibrin glue and oxidized regenerated cellulose
maintain a solid form when initially placed in direct con-
tact with urine and then assume a semisolid gelatinous
state. Polyethylene glycol forms a solid clot initially and
does not change after 5 days. Only hemostatic gelatin
matrix remained as a fine particulate suspension in both
normal and sanguineous urine so that the implications of
these findings with regard to sealing the renal paren-
chyma or the collecting system are still to be evaluated
[33]. Nonetheless, nowadays the haemostatic agents are
still expensive so that it has been proposed their use in
major surgical procedures and in acute life-threatening
hemorrhages or otherwise in moderately critical patients
with severe concomitant diseases or coagulation disor-
ders. The cost of the kit of Floseal is in US 85 dollars. Dif-
ferently from Floseal the ISC is an equipment which,
although more expensive at the beginning, allow to treat
several patients even if with longer time to haemostasis
according to our results. Also adverse events have been
reported in several fields as consequence of the use of gel-
atin-thrombin. HAs may elicit a foreign body reaction
leading to large giant cell granuloma, mimicking a meta-
static disease [34,35]. HAs, frequently used during
abdominal surgery, are linked to adhesion formation: a
case of early post-operative small bowel obstruction dur-
ing laparoscopic staging for endometrial cancer has been
described, underling that the use of haemostatic agents
should be considered as a cause in the differential diagno-
sis in patients with early post-operative bowel obstruc-
tion [36-38]. Not the least, application of FloSeal in the
lumpectomy cavity has resulted in benign mammogra-Pace et al. World Journal of Surgical Oncology 2010, 8:37
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phyc microcalcifications that could be misinterpreted as
malignant [39]. Therefore, it is crucial to get a better
understanding of the genesis of those reactions.
Ahead of its time are, on one hand, the recently applica-
tions of HAs in the premature rupture of membranes
where the adhesive sealants confer mechanical support to
the membrane and form a water tight seal [40]. On the
other hand, in the prostate cancer research frontiers, has
been evaluated the potential use of intra-operative gelatin
matrix haemostatic sealant embedded with macrophages
transduced with murine interleukin 12 recombinant ade-
noviral vector for prevention of recurrence of prostate
cancer following RP [41].
To our knowledge this is the first study which compare
the use of a HA and of the ISC in the enucleoresection of
RCC. The recent evidence related to the NSS capable, in
selected cases, to offer the same results of partial and rad-
ical nephrectomy as regard the overall cancer-specific
survival and the progression free survival, open the way
to look for minimally invasive approach without the
necessity of renal hilar clamping, avoiding the risks
related to warm ischemia time. Bleeding of the kidney
wound is usually controlled by bipolar coagulation and by
suturing, potentially increasing the induced tissue dam-
age by heat and by sutures. According with our results, it
should be easily achieved, in selected patients with RCC
of limited dimension, by using topic HAs or the ISC.
Overall, in our procedure also the need of suturing was
not required minimizing the operative time without any
risk of further intra- or post- operative bleeding. Even if,
it has been reported the use of thrombin-gelatin haemo-
static matrix for both oozing and focal hemorrhage and
effective even for high-flow bleeding, according with our
experience, we suggest to apply HAs to control localized
bleeding, for tumors of 7 cm or less of diameter. We pro-
pose to make use of those different way of achieving hae-
mostasis considering the satisfying results, their handling
and their efficacy, in the enucleoresecton of RCC looking
to a further employ also in the nerve sparing RRP. Never-
t h e l e s s ,  t h o s e  h a e m o s t a t i c s  s h o u l d  a l s o  r e s u l t  i n  m o r e
patients, suffering from several comorbidities with conse-
quence coagulation disorders, being able to undergo min-
imally invasive NSS. Even if we agree that HAs is the way
to go, they are not free from adverse reactions such as the
crea tion of inflammation and necrosis with the risk of
adhesions formation, whose genesis need to be clarified
and which claim further studies to improve the design of
these agents in future. Moreover, additional investiga-
tions will clarify the indications and the best HAs to
choose.
Looking to the future, minimally invasive surgery will
further drive the use of topical HA in the urologic field.
They offer promising employ in the laparoscopic and
robotic surgery to avoid the intricacy of the laparoscopic
sutures, to achieve rapidly hemostat in life-risk hemor-
r h a g e s  i n  c o m p l i c a t e  s i t u a t i o n s  l i k e  d u r i n g  w a r s  o r  i n
patients with an altered coagulation status.
Conclusions
Our results show Floseal and ISC to be both safe and effi-
cacy in achieving haemostasis in the enucleoresection of
RCC in T1a stage, with a less intra-operative and post-
operative blood loss as well as a shorter time to haemo-
stasis of Floseal in respect to ISC.
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